Table 5. Most common grade ≥3 TEAEs occurring in ≥10% of patients by preferred term (safety population).
| Preferred term, n (%) | DLBCL cohorts (combined) n = 89 | All lymphomas N = 124 |
|---|---|---|
| Patients with grade ≥3 TEAE | 85 (96) | 119 (96) |
| Increased amylase | 28 (31) | 36 (29) |
| Neutropenia | 26 (29) | 34 (27) |
| Hypophosphatemia | 19 (21) | 32 (26) |
| Anemia | 15 (17) | 23 (19) |
| Blood CPK increased | 15 (17) | 22 (18) |
| Lipase increased | 15 (17) | 22 (18) |
| Thrombocytopenia | 13 (15) | 19 (15) |
| Pneumonia | 7 (8) | 14 (11) |
| Pyrexia | 8 (9) | 13 (10) |
| AST increased | 11 (12) | 12 (10) |
TEAEs are defined as any adverse event that occurs after administration of the first dose of study treatment through 28 days after the last dose of study treatment, or until the start of subsequent antineoplastic therapy.